Evers J, Renner E, Bechtel W D
Br J Clin Pharmacol. 1983;16 Suppl 2(Suppl 2):309S-313S. doi: 10.1111/j.1365-2125.1983.tb02305.x.
Kinetics of brotizolam (0.25 mg) were studied in patients with different degrees of renal failure after single and repeated oral ingestion. Serum levels were analysed by radio-immunoassay. Patients were divided into three groups according to their renal function, i.e. creatinine clearance values of 45-80, 15-45, or less than 15 ml/min. The mean elimination half-life was 6.9-8.15 h, with a considerable variation of the peak concentration and elimination half-life in slight to moderate renal failure. There was no delay in elimination in severe renal failure and there was no drug accumulation. No dose adjustment is necessary for brotizolam in renal failure.
在不同程度肾功能衰竭患者单次及重复口服布替唑仑（0.25毫克）后，对其动力学进行了研究。通过放射免疫分析法分析血清水平。根据患者肾功能将其分为三组，即肌酐清除率值分别为45 - 80、15 - 45或小于15毫升/分钟。平均消除半衰期为6.9 - 8.15小时，在轻度至中度肾功能衰竭时，峰浓度和消除半衰期有相当大的变化。重度肾功能衰竭时消除无延迟，且无药物蓄积。肾功能衰竭患者使用布替唑仑无需调整剂量。
